With the snip of a gene, scientists hope to erase high cholesterol for life
Scientists have made progress in developing a single-time treatment for high cholesterol using CRISPR gene-editing therapy. The therapy has been shown to safely and continuously lower cholesterol and triglycerides for a year in a first-in-human trial. This treatment aims to reduce 'bad' cholesterol levels for life by editing a gene responsible for cholesterol production. The trial results indicate a significant reduction in cholesterol levels, offering hope for a long-term solution.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The CRISPR gene-editing therapy has been shown to safely and continuously lower cholesterol and triglycerides for a year.
- ✓ The therapy targets the PCSK9 gene, which is responsible for cholesterol production.
- ✓ High cholesterol is a major risk factor for heart disease.
What changed
The Cleveland Clinic's first-in-human trial of CRISPR gene-editing therapy demonstrated sustained cholesterol reduction for a year, marking a significant milestone in the development of this treatment.
Live updates
-
Experimental Gene-Editing Therapy Lowers Cholesterol for a Year
Scientists have made progress in developing a single-time treatment for high cholesterol using CRISPR gene-editing therapy. The therapy has been shown to safely and continuously lower cholesterol and triglycerides for a year in a first-in-human trial. This treatment aims to reduce 'bad' cholesterol levels for life by editing a gene responsible for cholesterol production. The trial results indicate a significant reduction in cholesterol levels, offering hope for a long-term solution.
Why it matters
High cholesterol is a major risk factor for heart disease, which is a leading cause of death worldwide. Current treatments often require lifelong medication and lifestyle changes. A one-time gene-editing therapy could revolutionize the management of high cholesterol and cardiovascular disease. The CRISPR gene-editing therapy targets the PCSK9 gene, which plays a key role in regulating cholesterol levels.
What is confirmed
- The CRISPR gene-editing therapy has been shown to safely and continuously lower cholesterol and triglycerides for a year.
- The therapy targets the PCSK9 gene, which is responsible for cholesterol production.
- High cholesterol is a major risk factor for heart disease.
Still unconfirmed
- CRISPR Therapeutics plans to pursue the highest dose of its lipid-lowering gene editing therapy.
What to watch next
- Further trials to confirm the efficacy and safety of the therapy
- Regulatory approval for widespread use
- Long-term results beyond one year
confidence 85%Sources used for this update (5)
- The New York Times — An Experimental Single-Time Treatment Slashed Cholesterol for a Year
- Cleveland Clinic Newsroom — Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year
- CNN — Snipping a gene to reduce bad cholesterol for life looks possible
- Time Magazine — A One-Time Treatment for High Cholesterol Shows Promising Results
- Endpoints News — #ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community